Company Encyclopedia
View More
name
X4 Pharmaceuticals
XFOR.US
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd.
1.902 T
XFOR.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking123/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-156.87%E
    • Profit Margin-279.86%E
    • Gross Margin80.11%A
  • Growth ScoreB
    • Revenue YoY2925.73%A
    • Net Profit YoY-467.43%E
    • Total Assets YoY-8.20%E
    • Net Assets YoY3.35%C
  • Cash ScoreB
    • Cash Flow Margin-35.73%D
    • OCF YoY2925.73%A
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreD
    • Gearing Ratio62.33%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research

    Zacks Research downgraded X4 Pharmaceuticals (NASDAQ:XFOR) from a "strong-buy" to a "hold" rating. Other analysts have mixed ratings, with an average rating of "Hold" and a consensus price target of $33.67. The stock opened at $3.68 on Wednesday. X4 Pharmaceuticals reported a Q3 EPS of ($0.69), beating estimates by $0.10. Institutional investors own 72.03% of the stock.

    Market Beat·
    US
    XFOR
    +0.77%
    Market Beat·
    US
    XFOR
    +0.77%

    Cantor Fitzgerald Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)

    Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on X4 Pharmaceuticals with a $14.00 price target. Shares closed at $3.75, indicating significant upside potential. Kluska, a 5-star analyst, has a 26.9% average return. X4 Pharmaceuticals has a Moderate Buy consensus with a $6.25 price target, suggesting a 66.67% upside. H.C. Wainwright also reiterated a Buy rating with a $5.00 target.

    Tip Ranks·
    US
    XFOR
    +0.77%
    Tip Ranks·
    US
    XFOR
    +0.77%

    X4 Pharmaceuticals to Join Guggenheim Healthcare Innovation Conference

    X4 Pharmaceuticals will participate in the Guggenheim Second Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. The company will hold a fireside chat on November 10 at 8:30 a.m. ET and will be available for one-on-one meetings with investors.

    Reuters·
    US
    XFOR
    +0.77%
    Reuters·
    US
    XFOR
    +0.77%

    X4 Pharmaceuticals | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 1.765 M

    LB filings·
    US
    XFOR
    +0.77%
    LB filings·
    US
    XFOR
    +0.77%

    X4 Pharmaceuticals | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 1.765 M

    LB filings·
    US
    XFOR
    +0.77%
    LB filings·
    US
    XFOR
    +0.77%
    © 2025 Longbridge｜Disclaimer